Vicor Technologies, Inc. (OTCBB: VCRT) LPD2i-VS™ Tested by U.S. Army Institute of Surgical Research (USAISR)

Vicor Technologies, Inc. (OTCBB: VCRT)

LPD2i-VS™ Tested by U.S. Army Institute of Surgical Research (USAISR)

Determined to minimize mortality rate of battlefield casualties, the U.S. Army Institute of Surgical Research has been working with Vicor’s PD2i-VS system through a research collaboration and has tested it against the best methodologies currently available. In extensive real-world testing involving several studies with data provided by the USAISR, the PD2i-VS™ has proven to be more predictive than all other compared technologies.

In Vicor’s most recent study with Army provided data, the PD2i-VS™ examined 325 civilian trauma injury victims, twenty of whom would later die of their injuries. Incredibly, the PD2i-VS™ correctly identified all twenty.

Even more importantly, of the twenty who died, conventional trauma triaging techniques had selected only six for lifesaving intervention in the field.

This suggests both that current trauma triage methods are woefully inadequate, and that the PD2i-VS™ is poised to make an extraordinary contribution to combat and trauma survival in the near future.

The very low PD2i™ values demonstrated in the chart at above right signify imminent risk of “crashing”, revealing dire need of aggressive medical intervention.